Back to Network
11
Shared Docs
11
Same-Page
11 / 11
Mentions
Document Mentions (11 shared documents)
2 mentions1 same-page
Page ?Same page
ng scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergen, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Allergen (AGN) - BAML reaffirming BUY
pital to drive shareholder return. Next catalyst will be 2Q earnings/2/116 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where s
2 mentions1 same-page
Page ?Same page
esult In an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. EFTA00821588 Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Allergen (AGN) - BAML reaffirming BUY
capital to drive shareholder return. Next catalyst will be 2Q eamings/2H16 Outlook on 8/8. AGN Is on our firm's US-1 list of best Investment Ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning In generic pharma where sc
2 mentions1 same-page
Page ?Same page
ng scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergen, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Allergen (AGN) - BAML reaffirming BUY
pital to drive shareholder return. Next catalyst will be 2Q earnings/V.116 Outlook on 8/8. AGN Is on our firm's US-1 list of best investment Ideas. Teva Pharma (TWA) - BAML reiterating BUY on TEVA after the FTCs approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where sca
Sponsored
2 mentions1 same-page
Page ?Same page
ng scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva and Frontier Communications are three names we have hi=h conviction on and they have mandatory convert preferreds that I recommend buying. Allergan (AGN) - BAML rea=firming BU
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
2 mentions1 same-page
Page ?Same page
ng scale, can result in an attractively skewed upside vs downsi=e profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications ar= three names we have high conviction on and they have mandatory convert pr=ferreds that I recommend buying. 3 EFTA_R1_01556244 EFTA02454470
l to drive shareholder return. N=xt catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm :=17;s US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval=of AGN generics deal. We continue to like TEVA's positioning in generic=pharma where
2 mentions1 same-page
Page ?Same page
ng scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva and Frontier Communications are three names we have hi=h conviction on and they have mandatory convert preferreds that I recommend buying. 7 EFTA_R1_01557877 EFTA02455324
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
Sponsored
2 mentions1 same-page
Page ?Same page
g scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. EFTA_R1_00024532 EFTA01737704 All
pital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
2 mentions1 same-page
Page ?Same page
ng scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Allergan (AGN) - BAML reaffirming BU
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
2 mentions1 same-page
Page ?Same page
ng scale, can result in an attractively skewed upside vs downside profile for holding the mandatory convert vs the common stock. Allergan, Teva and Frontier Communications are three names we have high conviction on and they have mandatory convert preferreds that I recommend buying. Allergan (AGN) - BAML reaffirming BU
apital to drive shareholder return. Next catalyst will be 2Q earnings/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We continue to like TEVA's positioning in generic pharma where
Sponsored
2 mentions1 same-page
Page ?Same page
ng scale, can result in an att=actively skewed upside vs downside profile for holding the mandatory conve=t vs the common stock. Allergan, Teva and Frontier Communications are three names we have hi=h conviction on and they have mandatory convert preferreds that I recommend buying. Allergan (AGN) - BAML rea=firming BU
apital to drive shareholder return. Next catalyst will be 2Q earni=gs/2H16 Outlook on 8/8. AGN is on our firm's US-1 list of best investment ideas. Teva Pharma (TEVA) - BAML=reiterating BUY on TEVA after the FTC's approval of AGN generics deal. We co=tinue to like TEVA's positioning in generic pharma where
Sponsored
Mutual Connections (35)
Entities connected to both Frontier Communications and Teva Pharma
Richard Kahn
PERSON45 w/ Frontier·11 w/ Teva
Marc Rich
PERSON29 w/ Frontier·11 w/ Teva
Jeffrey Epstein
PERSON17 w/ Frontier·11 w/ Teva
Bloomberg L.P.
ORGANIZATION12 w/ Frontier·11 w/ Teva
Chart One
ORGANIZATION11 w/ Frontier·11 w/ Teva
Paul Volcker
PERSON11 w/ Frontier·11 w/ Teva
HM
Hans Mikkelsen
PERSON11 w/ Frontier·11 w/ Teva
US Treasury ETF
ORGANIZATION11 w/ Frontier·11 w/ Teva
S&P500 ETF
ORGANIZATION11 w/ Frontier·11 w/ Teva
Investment Grade Supply
ORGANIZATION11 w/ Frontier·11 w/ Teva
Investment Grade ETF
ORGANIZATION11 w/ Frontier·11 w/ Teva
Frontier Comm
ORGANIZATION10 w/ Frontier·10 w/ Teva
Spec Pharma
ORGANIZATION10 w/ Frontier·10 w/ Teva
Allergan
LOCATION10 w/ Frontier·9 w/ Teva
AM
Amanda
PERSON8 w/ Frontier·8 w/ Teva
AE
Amanda Ens
PERSON7 w/ Frontier·7 w/ Teva
PR
Pfd Return
PERSON7 w/ Frontier·7 w/ Teva
Outlook
ORGANIZATION6 w/ Frontier·6 w/ Teva
Bloomberg: Junk Debt Keeps Climbing Despite Plunging Oil Prices
ORGANIZATION6 w/ Frontier·6 w/ Teva
Non-Farm Payrolls
ORGANIZATION6 w/ Frontier·6 w/ Teva